Scholarlink

Purpose of Review <p>The purpose of this review is to summarize current evidence regarding the mechanism underlying cardiovascular disease (CVD) in cancer patients and to provide guidance on optimal diagnostic and therapeutic approaches to coronary artery disease (CAD) and structural heart disease (SHD) in this vulnerable population.</p> Recent Findings <p>Currently, there are nearly 20&#xa0;million cancer survivors in the United States, and CVD is a leading cause of death in this patient population. Only approximately half of cancer patients with CVD are referred to cardiologists and receive guideline-directed medical therapy. Cancer patients are frequently excluded from large randomized clinical trials evaluating cardiovascular interventions, and in clinical practice these patients are often felt to be too high risk for intervention. However, recent data suggests that percutaneous coronary intervention and structural heart intervention may be of significant benefit in carefully selected patients.</p> Summary <p>A diagnosis of cancer should not preclude patients from receiving optimal medical therapy and even invasive coronary and structural therapies. Decisions regarding this complex patient population should involve a multidisciplinary approach to allow for patient-centric considerations to ensure optimal outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reframing Cardiovascular Interventions in Cancer Patients: Emerging Evidence and Evolving Paradigms

  • 期刊论文

  • 发表日期：

    2026年1月3日

查看全文
  • Ryan Kabir,
  • William Fearon,
  • Juyong Brian Kim

摘要

Purpose of Review

The purpose of this review is to summarize current evidence regarding the mechanism underlying cardiovascular disease (CVD) in cancer patients and to provide guidance on optimal diagnostic and therapeutic approaches to coronary artery disease (CAD) and structural heart disease (SHD) in this vulnerable population.

Recent Findings

Currently, there are nearly 20 million cancer survivors in the United States, and CVD is a leading cause of death in this patient population. Only approximately half of cancer patients with CVD are referred to cardiologists and receive guideline-directed medical therapy. Cancer patients are frequently excluded from large randomized clinical trials evaluating cardiovascular interventions, and in clinical practice these patients are often felt to be too high risk for intervention. However, recent data suggests that percutaneous coronary intervention and structural heart intervention may be of significant benefit in carefully selected patients.

Summary

A diagnosis of cancer should not preclude patients from receiving optimal medical therapy and even invasive coronary and structural therapies. Decisions regarding this complex patient population should involve a multidisciplinary approach to allow for patient-centric considerations to ensure optimal outcomes.